RIVAROXABAN S.K. 2.5 MG

Nazione: Israele

Lingua: inglese

Fonte: Ministry of Health

Principio attivo:

RIVAROXABAN

Commercializzato da:

K.S.KIM INTERNATIONAL (SK- PHARMA) LTD., ISRAEL

Codice ATC:

B01AF01

Forma farmaceutica:

FILM COATED TABLETS

Composizione:

RIVAROXABAN 2.5 MG

Via di somministrazione:

PER OS

Tipo di ricetta:

Required

Prodotto da:

PHAROS – PHARMACEUTICAL ORIENTED SERVICES SINGLE MEMBER LTD, GREECE

Area terapeutica:

RIVAROXABAN

Indicazioni terapeutiche:

Rivaroxaban S.K, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel , is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.Rivaroxaban S.K,, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.

Data dell'autorizzazione:

2023-05-08

Foglio illustrativo

PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS’
REGULATIONS (PREPARATIONS) – 1986
The medicine is dispensed with a doctor's prescription only
Rivaroxaban S.K. 2.5 mg
Film-coated tablets
Each film-coated tablet contains:
Rivaroxaban 2.5 mg
For information regarding inactive ingredients: see section 2 –
“Important information
about some of the ingredients of the medicine” and section 6 –
“Additional
information”.
Read the entire leaflet carefully before using the medicine.
This leaflet contains
concise information about the medicine. If you have additional
questions, refer to the
doctor or the pharmacist.
This medicine has been prescribed for your treatment. Do not pass it
on to others. It
may harm them even if it seems to you that their medical condition is
similar.
1.
What is the medicine intended for?
•
Rivaroxaban S.K, co-administered with acetylsalicylic acid (ASA) alone
or with
ASA plus clopidogrel , is indicated for the prevention of
atherothrombotic
events in adult patients after an acute coronary syndrome (ACS) with
elevated
cardiac biomarkers.
•
Rivaroxaban S.K,, co-administered with acetylsalicylic acid (ASA), is
indicated
for the prevention of atherothrombotic events in adult patients with
coronary
artery disease (CAD) or symptomatic peripheral artery disease (PAD) at
high
risk of ischaemic events
Therapeutic class:
Rivaroxaban S.K.
2.5 mg belongs to a class of medicines called
anticoagulants, and acts by reducing the tendency to produce blood
clots by blocking
a factor involved in the clotting process (factor Xa).
2.
Before using the medicine
Do not use this medicine if:
Do not take Rivaroxaban S.K.
2.5 mg and inform your doctor if any of the above
mentioned conditions apply to you.
Special warnings regarding the use of the medicine
Talk to the doctor or pharmacist before taking Rivaroxaban S.K.
2.5 mg.
Do not use Rivaroxaban S.K.
2.5 mg in combination with certain drugs that reduce
blood clotting such as prasugrel or ticagrelor, except for
acetylsalicylic acid (aspirin)
and clo